-
1 Comment
HAEMATO AG is currently in a long term downtrend where the price is trading 18.4% below its 200 day moving average.
From a valuation standpoint, the stock is 100.0% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 0.2.
Based on the above factors, HAEMATO AG gets an overall score of 1/5.
Industry | Drug Manufacturers - Specialty & Generic |
---|---|
Exchange | F |
CurrencyCode | EUR |
ISIN | DE0006190705 |
Sector | Healthcare |
Market Cap | 53M |
---|---|
Beta | 1.37 |
PE Ratio | 17.46 |
Target Price | 7.75 |
Dividend Yield | 9.8% |
HAEMATO AG, together with its subsidiaries, operates in the pharmaceutical sector in Germany. The company distributes European import medicinal products; and manufactures and distributes its own generic medicinal products. It provides pharmaceuticals in the areas of oncology, HIV/AIDS, rheumatism, neurology, and cardiovascular diseases; and products for aesthetic treatments. The company also develops and commercializes pharmaceutical, medicinal, and medical engineering products for aesthetic surgery and cosmetic dermatology. It serves wholesalers and pharmacies, as well as doctors and hospitals. The company was founded in 1993 and is headquartered in Schönefeld, Germany. HAEMATO AG is a subsidiary of MPH Health Care AG.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for HAE.F using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025